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Edited by Maurice MontalAbstract The mechanism of human ether-a`-go-go-related gene
(HERG) K+ channel blockade by the antifungal agent ketocon-
azole was investigated using patch-clamp recording from mam-
malian cell lines. Ketoconazole inhibited whole-cell HERG
current (IHERG) with a clinically relevant half-maximal inhibi-
tory drug concentration (IC50) value of 1.7 lM. The voltage-
and time-dependent characteristics of IHERG blockade by keto-
conazole indicated dependence of block on channel gating, ruling
out a signiﬁcant role for closed-state channel inhibition. The S6
HERG mutations Y652A and F656A produced 4-fold and
21-fold increases in IC50 for IHERG blockade, respectively.
Thus, ketoconazole accesses the HERG channel pore-cavity on
channel gating, and the S6 residue F656 is an important determi-
nant of ketoconazole binding.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The cardiac rapid delayed rectiﬁer potassium current (IKr),
carried by channels encoded by the human ether-a`-go-go-re-
lated gene (HERG), plays an important role in ventricular
repolarisation and in determining the QT-interval of the elec-
trocardiogram [1,2]. HERG channel blockade by therapeuti-
cally and structurally diverse drugs results in the acquired
form of long QT syndrome [1–3]. A detailed insight into the
HERG channel drug receptor site(s) is key to the production
of pharmacophore models that may help eliminate potential
HERG-blocking drugs early in the drug development process
[3–5].
The majority of HERG-blocking drugs that have been
examined in detail are thought to cross the cell membrane,
to gain access to the channel pore cavity when channels acti-Abbreviations: ANOVA, analysis of variance; C.I., 95% conﬁdence
intervals; HEK, human embryonic kidney; HERG, human ether-a`-go-
go-related gene; IC50, half-maximal inhibitory drug concentration;
IHERG, current mediated by the HERG channel; IKr, rapid delayed
rectiﬁer current; KETO, ketoconazole; [K+]e, external potassium
concentration; nH, Hill coeﬃcient; t1/2, time taken for the tail current
to decline to half of its peak value; WT, wild type
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residues Y652 and/or F656 [2,6–11]. Drugs that do not con-
form to this general scheme may provide an important
means of identifying additional drug binding site(s) on the
HERG channel. One such agent may be the imidazole anti-
fungal drug ketoconazole (KETO), which in a study con-
ducted on HERG-transfected Xenopus oocytes was
suggested to inhibit HERG current (IHERG) tonically, with-
out a requirement for prior channel activation [12]. This
has subsequently been interpreted as indicating that KETO
exhibits preferential closed-channel state IHERG blockade
[2,13]. However, a recent study of a related imidazole drug
miconazole has shown that this drug binds preferentially to
activated channels and to a receptor site involving the
F656 residue [14]. Comparable data for KETO are at present
lacking. Therefore, we have investigated the mechanism of
IHERG blockade by KETO, in experiments performed at
mammalian physiological temperature. Our ﬁndings demon-
strate that inhibition of IHERG by KETO does require chan-
nel gating and involves drug-binding at the canonical
binding site on the HERG channel.2. Materials and methods
2.1. Electrophysiological recording from mammalian cell lines stably
expressing HERG
Whole-cell patch-clamp measurements of wild-type (WT) IHERG
were made at 37 ± 1 C from human embryonic kidney (HEK) 293
cells stably expressing HERG (generously donated by Dr. Craig Jan-
uary, University of Wisconsin [15]) or from another cell line stably
expressing lower levels of HERG developed in this laboratory [11].
HEK 293 cells stably expressing the S6 HERG mutants Y652A and
F656A were also employed [11]. Data were acquired as described pre-
viously [11,16,17]. Normal extracellular Tyrode’s solution contained
(in mM): 140 NaCl, 4 KCl, 2.5 CaCl2, 1 MgCl2, 10 Glucose, 5
HEPES, (titrated to pH 7.45 with NaOH). For experiments employ-
ing the S6 mutant F656A, and its WT control, the external solution
contained 94 mM KCl (the NaCl concentration was correspondingly
reduced) [17,18]. The pipette dialysis solution for IHERG measurement
contained (in mM): 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP, 10
HEPES (titrated to pH 7.2 with KOH). No correction was made
for the ‘pipette-to-bath’ liquid junction potential, which was measured
to be 3.2 mV.2.2. Concentration–response data correction for IHERG run-down
In this study KETO was found to exhibit a progressive rather than
rapid development of IHERG blockade (Fig. 1Ai). Control experiments
were performed in order to monitor, and allow correction of concen-
tration–response data for current run-down. The approach used wasblished by Elsevier B.V. All rights reserved.
Fig. 1. Concentration dependent inhibition of IHERG by KETO. (Ai) shows representative currents of IHERG in control and after 1, 5, 9 and 10 min
of exposure to 1 lMKETO (upper traces). The lower trace shows the voltage protocol used. (Aii) Concentration-dependent inhibition of peak IHERG
tails (n = 5 cells per concentration). (Bi) The upper traces are representative currents in control and after 10 min exposure to 1 lMKETO (elicited by
voltage protocol shown in the lower trace). The portion of the current traces on repolarisation to 40 mV shows tail current cross-over. (Bii) Mean
(±S.E.M.) t1/2 values, illustrating that there was a signiﬁcant increase in the time taken for the tail currents to decline to 50% of their peak amplitude
in the presence of 1 lM KETO (*denotes statistical signiﬁcance; n = 5).
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developing block following drug application [17,18]. Cells were pulsed
repeatedly for a stabilisation period (3 min), followed by a 10-min
recording period in normal Tyrode’s solution, using the same protocol
as used to quantify concentration-dependence of IHERG blockade
(shown in Fig. 1Bi). The mean level of run-down of peak outward
WT IHERG tails, measured in 4 mM external potassium [K
+]e and elic-
ited at 40 mV, following voltage commands to +20 mV over 10 min
was 13.9 ± 1.5% (n = 6). The experiments investigating the concentra-
tion-dependence of inhibition were performed in an identical manner
to those used to quantify IHERG run-down. Concentration–response
data were corrected for IHERG run-down by subtracting the mean level
of run-down from the last tail current in the stabilisation period and
the value obtained was used to calculate fractional block attained by
exposure to KETO for 10 min (cf. [17,18]).
The gradual onset of KETO’s actions was straightforward to correct
for potential run-down, when using a simple test-pulse protocol to a
single test potential value. However, in order to avoid possible correc-
tion errors during other voltage-protocols employed, isochronal cur-
rent measurements after relatively short periods of exposure to
KETO were made (to minimise run-down; a previously described strat-
egy [17,18]). Consequently, other than concentration–response data
(Figs. 1 and 4), the results presented do not represent steady-state drug
eﬀects.
2.3. Data analysis
The standard equations used in graphical ﬁts to the data are de-
scribed elsewhere [11,19]. Statistical comparisons were made using
paired and unpaired t-tests or one way analysis of variance (ANOVA),
with a Bonferroni post-test where appropriate (Graphpad Inc.). P val-
ues of less than 0.05 were taken as signiﬁcant.
2.4. Drugs
KETO powder (Sigma) was dissolved in DMSO to produce an ini-
tial stock solutions of either 50 mM or 100 mM, which were serially di-
luted to produce stock solutions ranging to 50 lM. The KETO stock
solutions were diluted 1:1000-fold (or 1:500-fold for the highest con-
centration used in the mutant concentration-dependence experimentsin Fig. 4) with Tyrode’s solution to achieve concentrations stated in
the Results. One set of experiments employed in-house Fmoc synthes-
ised BeKm-1 toxin solution, prepared as described previously [20].
Additionally, in experiments employing E-4031 (generously donated
by Eisai, Japan), the stock solution was made up in Milli-Q water
and the test concentration was produced by a 1:1000-fold dilution with
Tyrode’s solution.3. Results and discussion
3.1. Concentration-dependence of IHERG inhibition by KETO
This was determined by repetitive application (every 12 s) of
a 2-s step depolarisation from a holding potential of 80 to
+20 mV followed by a 4-second repolarising step to 40 mV.
Fig. 1Ai shows that 1 lM KETO produced a progressive inhi-
bition of IHERG over 10 min of drug application. Data from a
minimum of 5 cells were obtained for each of ﬁve diﬀerent
drug concentrations and the mean fractional block of the
IHERG tail at each concentration was calculated and plotted
as shown in Fig. 1Aii. The half-maximal inhibitory concentra-
tion (IC50), derived from ﬁtting the data with a Hill equation,
was 1.7 ± 0.3 lM with a Hill coeﬃcient (nH) of 0.9 ± 0.1. This
value is in the order of 25-fold lower than that reported in a
previous study in which HERG channels were expressed in
Xenopus oocytes [12], but is close to recently reported values
of 1.3 and 1.9 lM obtained at 35–37 C from a mammalian
cell line expression system [4,13]. Moreover, it compares with
a therapeutic KETO serum concentration level of 10 lM
[21]; therefore KETO blockade of HERG channels occurs at
clinically relevant drug concentrations. Fig. 1Bi displays super-
imposed currents in control, and in the presence of 1 lM
KETO (from the same cell as in Fig. 1Ai), with a greater por-
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in these experiments decaying tail currents in control and drug
crossed over one-another. This eﬀect was quantiﬁed by calcu-
lating the time taken for the tail current to decline to half of its
peak value (t1/2; plotted in Fig. 1Bii). The value in KETO was
signiﬁcantly larger, and deactivation therefore slower, than
that in control (P < 0.01; n = 5). A slowing of deactivation
has been reported for a number of other HERG-blocking
drugs including ibutilide [22], verapamil [23], cocaine [24]
and chloroquine [25]. Tail current cross-over can be explained
either by: (i) the occurrence of some drug unbinding on repo-
larisation leading to reduced blockade, an increase in IHERG
and, consequently, an apparent slowing of deactivation of
the IHERG tail; (ii) if a drug that has bound to the open channel
unbinds on repolarisation more slowly than the process of
deactivation, thereby interfering with closure of the activation
gate. This phenomenon was ﬁrst described by Armstrong [26]
who coined the phrase ‘‘foot in the door’’ to describe such an
interaction [27]. The cross-over phenomenon is inconsistent
with a primarily closed-channel blocking mechanism.
3.2. Time-dependence of block
Dependence of IHERG blockade upon channel gating should
be reﬂected in time-dependent development of current inhibi-
tion on membrane depolarisation. This was investigated for
KETO using two protocols. In the ﬁrst, a 10-s depolarising
step to 0 mV was applied in the absence of KETO, was discon-
tinued during 3 min of exposure to 5 lM KETO and was then
reapplied in the maintained presence of drug. Fig. 2Ai shows
representative current traces in the absence and presence of
KETO. The fractional block was calculated at diﬀerent time-
points throughout the protocol and the mean fractional blockFig. 2. Time-dependence of inhibition of IHERG by KETO. (Ai) Representat
(lower trace), in the absence (Control) and the ﬁrst trace elicited after 3 min ex
against time following onset of depolarisation (n = 6; protocol as for Ai). (B
duration voltage steps to +40 mV in Control and after 3 min exposure to
(±S.E.M.) fractional block calculated after 10, 20, 200 and 500 ms duration s
step (n = 5) but there was a signiﬁcant increase after 20 ms. The fractional bdata were plotted against time (Fig. 2Aii). Inhibition devel-
oped progressively with time following depolarisation to
0 mV, with no signiﬁcant increase in block level observed after
1500 ms. This observation would argue against closed-chan-
nel inhibition and for a dependence of IHERG blockade on
channel gating. The second protocol employed a holding po-
tential of 100 mV to ensure that all the channels were closed
when they were exposed to drug [11,20]. Depolarising steps to
+40 mV of diﬀering duration were alternately applied: one
short (10 or 20 ms) step followed 12 s later by a longer (200
or 500 ms) step. Each step to +40 mV was followed by a
500 ms step to 40 mV in order to monitor tail current ampli-
tude prior to returning the membrane potential to 100 mV.
This protocol was applied ﬁrst in control conditions, was dis-
continued during 3 min application of 5 lM KETO, and was
then reapplied. Fig. 2Bi shows representative currents in the
absence and presence of 5 lM KETO using pulses of 10 and
200 ms. Initial current on repolarisation following a 10 ms
pulse was similar in control and KETO. The two traces then
diverged, which may reﬂect the development of inhibition of
the small IHERG present at 40 mV. With the 200 ms pulse,
time-dependent development of inhibition can be seen during
the ﬁrst 40–50 ms of the pulse to +40 mV, with substantial
block of the IHERG tail evident. Mean fractional block data
for each of the four pulse durations used are presented as a
bar chart in Fig. 2Bii. There was no signiﬁcant inhibition of
the current immediately after the 10 ms step (P = 0.50;
n = 5), indicating no component of closed-channel inhibition.
Some block was evident following the 20 ms depolarisation
(P < 0.05; n = 5), whilst substantial block was seen with 200
and 500 ms duration pulses (block at these two time-points
did not signiﬁcantly diﬀer; P = 0.74; n = 5). Considered collec-ive currents (upper traces) elicited by a 10-s depolarising step to 0 mV
posure to 5 lMKETO. (Aii) Mean (±S.E.M.) fractional block plotted
i) Representative currents (upper traces) elicited by 10 ms and 200 ms
5 lM KETO. The protocol is shown in the lower traces. (Bii) Mean
teps to +40 mV. There was no signiﬁcant fractional block after a 10 ms
lock was similar between the 200 and 500 ms steps.
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block by KETO depends on channel gating.
3.3. Proﬁle of IHERG inhibition by KETO during a voltage-ramp
We reasoned that the use of a voltage-ramp protocol would
allow the eﬀects of HERG channel gating on the development
of IHERG blockade by KETO to be surveyed rapidly using a
single command waveform. Therefore, an ascending ramp pro-
tocol was applied in control conditions, was discontinued dur-
ing 3 min of drug exposure and was then repeated. Fig. 3Ai
shows representative current records (upper traces) in control
and KETO (the voltage protocol is shown in lower traces;
ramp velocity:10 mV/s from 80 to +40 mV). Current in con-
trol activated positive to 50 mV and peaked between 10
and 0 mV. The fractional block was calculated at 10 mV incre-
ments between 40 and +40 mV for each cell (Fig. 3Aii).
Block was seen to develop progressively during the ramp,
reaching a maximal level at +10 mV; ANOVA analysis of
fractional block at the diﬀerent points during the ramp showed
a signiﬁcant dependence of block on ramp voltage (P < 0.001;
n = 5). If IHERG blockade involved the drug binding predomi-
nantly to closed channels, substantial IHERG inhibition might
have been predicted to occur at negative voltages early during
the ascending ramp, but this was not the case. This approach
was validated in a positive control experiment using a toxin
inhibitor of HERG channels, BeKm-1, which binds to the
external face of the HERG channel and has been shown to ex-
hibit preferential closed-channel state blockade [20,28]. The
proﬁle of IHERG blockade by BeKm-1 during the voltage-rampFig. 3. Eﬀect of changes in membrane potential. (Ai) Representative currents
to 5 lM KETO elicited by an ascending ramp voltage-command (shown in lo
10 mV increments between 40 and +40 mV during the voltage-ramp for 5
25 nM BeKm-1 (open squares, dashed line: n = 4). (Bi) Representative curren
lower trace: in control solution, following 3 min exposure to 5 lMKETO and
(n = 7) measured before (2000 ms), during (5000 ms) and after (10000 ms) the
during the step to +80 mV (P > 0.1).protocol was the inverse of that with KETO: inhibition was
greatest at negative voltages early in the ramp and declined
at more positive voltages later in the ramp. These observations
demonstrate clearly that BeKm-1 and KETO exhibited diﬀer-
ing blocking proﬁles and are inconsistent with a predominantly
closed-state channel blocking mechanism for KETO.
3.4. Eﬀect on IHERG block by KETO of strong membrane
depolarisation
In order to discriminate between dependence of drug action
on activated and inactivated channel states, we modiﬁed the
10-s step to 0 mV, by incorporating a 4-s step to +80 mV to
promote the transition of the HERG channels into the inacti-
vated state (Fig. 3Bi, upper traces show representative cur-
rents, lower trace shows voltage commands; see also
[11,16,19]). The protocol was applied in control solution, was
discontinued while the cell was exposed to 5 lM KETO for
3 min, and was then reapplied in the maintained presence of
KETO. The protocol was ﬁnally repeated in a saturating con-
centration of E-4031 (5 lM), to allow subtraction of any
endogenous/leak currents from total current in control and
in KETO, before calculating fractional block by KETO. This
was calculated before (2000 ms), during (5000 ms) and after
(10000 ms) the step to +80 mV (shown in Fig. 3Bii). Whilst
there was a trend for a reduction of the fractional block of
IHERG during the step to +80 mV, this did not attain statistical
signiﬁcance (P > 0.1; n = 7), suggesting that KETO does not
have a strong preference for activated over inactivated channel
states.(upper traces) in control and the ﬁrst trace elicited after 3 min exposure
wer trace). (Aii) Mean (±S.E.M.) fractional block values calculated at
lM KETO (closed squares, solid line; n = 6) and, for comparison, by
ts (upper traces) elicited by the three step voltage protocol shown in the
in the presence of 5 lME-4031. (Bii) Mean (±S.E.M.) fractional block
step to +80 mV. There was no signiﬁcant reduction in fractional block
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blockade
The S6 residues Y652 and F656, located on the inner helices
of the HERG channel, have been implicated as critical molec-
ular determinants of channel block by drugs that gain access to
the inner cavity of the channel upon channel gating [2,3,6,29].
Consequently, we tested the role of mutation of these two ami-
no-acid residues to alanine (Y652A and F656A) on the inhib-
itory eﬀect of KETO. First, we investigated the eﬀect of the
Y652A mutation on the concentration-dependence of inhibi-
tion of IHERG by KETO (in an identical fashion to that de-
scribed in Section 3.1 for WT-HERG). Figs. 4Ai and Aii
show representative WT- and Y652A-HERG currents elicited
by the protocol shown in the lower trace of Fig. 4Aii. The con-
centration–response relations for inhibition of WT- and
Y652A-IHERG are shown in Fig. 4Aiii. The Y652A mutation
produced a modest (4.3-fold) increase in the calculated IC50
value (P < 0.001). Concentration-dependent inhibition ofFig. 4. Eﬀect of S6 mutants Y652A and F656A on the action of KETO. (A) R
protocol shown in the lower trace of Aii, in the absence and presence o
Concentration–response relations for WT- and Y652A-HERG (n = 5 cells p
IC50 values are shown in the ﬁgure; corresponding nH values = 0.9 ± 0.1 for
(Bi) and F656A (Bii) currents, evoked by the voltage protocol shown in the in
(Bii) shows relevant portion of voltage-protocol during which currents in u
response relations for F656A-HERG and its corresponding WT-HERG
concentration for F656A). IC50 values are shown in the ﬁgure; correspondin
HERG.F656A-HERG and its WT-HERG control was also examined
using previously described recording conditions (inward IHERG
currents in high [K+]e [17,18] ) with the protocol shown in the
inset of Fig. 4Bi (representative traces are shown in Fig. 4Bi
and Bii). The concentration–response curves for WT- and
F656A-HERG expressing cells are shown in Fig. 4Biii. The
IC50 value for WT inward IHERG with this protocol was not
signiﬁcantly diﬀerent from that for WT outward IHERG
(Fig. 1Aii; P > 0.05). However, the F656A-HERG mutation
increased the IC50 for inhibition of IHERG by 20.6-fold;
(P < 0.001). These results indicate that the F656 residue is a
strong molecular determinant of channel block by KETO,
whilst Y652 exerts a more modest inﬂuence.
3.6. Implications of this study
This is the ﬁrst study of the mechanism of IHERG blockade
by KETO (i) to employ a mammalian expression system and
(ii) to examine molecular determinants of channel blockade.epresentative WT (Ai) and Y652A (Aii) currents, evoked by the voltage
f 20 lM KETO. Inset in Aii shows tail currents in close-up. (Aiii)
er concentration for WT and 4–5 cells per concentration for Y652A).
WT-HERG and 1.0 ± 0.04 for Y652A-HERG. (B) Representative WT
set of (Bi), in the absence and presence of 20 lMKETO. Lower trace in
pper panel of (Bii) and in (Bi) were recorded. (Biii) Concentration–
control (n = 4–5 cells per concentration for WT and 4–8 cells per
g nH values = 1.0 ± 0.1 for WT-HERG and 1.6 ± 0.1 lM for F656A-
2004 J.M. Ridley et al. / FEBS Letters 580 (2006) 1999–2005A previous investigation using Xenopus oocytes reported a to-
nic block of IHERG that did not require prior channel activa-
tion to occur [12]. It was concluded that the results were
consistent with KETO either blocking the closed-channel
state(s) or producing a very rapid open channel block [12].
Since that report, KETO has been considered to bind predom-
inantly to the closed-state(s) of the HERG channel [2,13,14].
Indeed, in a recent study investigating the impact of voltage
protocol on the potency of HERG channel blockers, KETO
was selected for study, along with BeKm-1, as a closed-state
channel blocker [13]. However, the two agents behaved diﬀer-
ently in that study – with potency of BeKm-1 block showing a
much greater dependence on voltage-protocol than did that of
KETO [13]. Our data provide an explanation for this diﬀer-
ence – in contrast to BeKm-1 [20], KETO is not a preferential
closed-state HERG channel blocker. Furthermore, our study
also resolves an apparent discrepancy between the mechanism
of action of KETO and the related imidazole, miconazole,
which has recently been reported to inhibit IHERG via a prefer-
ential activated-state channel blockade involving residue F656
[14]. In fact, IHERG block by both KETO and miconazole in-
volves channel gating. Distinguishing rapid open channel from
closed channel IHERG blockade can be diﬃcult [11,30]. The use
of brief (10–20 ms) depolarisations from a negative holding po-
tential in this study was important in distinguishing between
the two possibilities; such brief voltage commands have not
been used previously to characterise inhibition of IHERG by
KETO. Furthermore, the contrasting proﬁles of IHERG block-
ade by KETO and BeKm-1 during the ramp protocol in
Fig. 3A provide a clear demonstration that KETO’s action di-
verges from that expected for a closed-channel inhibitor. Per-
haps most signiﬁcantly, we have demonstrated that residue
F656, located in the channel’s inner cavity is an obligatory
component of the KETO binding site and it is diﬃcult to con-
ceive how this residue could be accessible for drug binding
without a requirement for channel gating. Therefore, we con-
clude that KETO should no longer be considered to be a pref-
erential closed-channel state HERG blocker. Instead, its
action involves binding within the HERG channel pore-cavity
at the canonical drug receptor-site involving the F656 (and to a
lesser extent Y652) residue, as a result of channel gating.
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